A Randomised Controlled Trial to Compare Efficacy and Tolerability of Plenvu and Picoprep as Cleansing Agents Before Colonoscopy

What this Trial Is About

Researchers are comparing two bowel cleansing agents, Plenvu and Picoprep, used before colonoscopy to check for colon disease, mainly to exclude cancer. This phase 4 trial investigates whether the newer, low-volume Plenvu is at least as effective as the established Picoprep in cleaning the bowel, while also examining patient tolerability and compliance. The study is conducted at a single center in North Jutland with 400 patients referred for colonoscopy. Participants are randomly assigned to receive either Picoprep or Plenvu. Picoprep involves taking two doses dissolved in water before the procedure, with fluid intake totaling approximately 2.3 liters. Plenvu is taken in a two-day regimen with two separate doses dissolved in 500 ml water each, accompanied by additional fluids for a total of 2 liters. Both agents require dietary restrictions before colonoscopy, including avoiding seed-containing foods five days prior and following a fluid diet the day before. During the study, participants complete a questionnaire about side effects and their experience with the bowel preparation before the colonoscopy. The colonoscopist, who does not know which agent was used, assesses bowel cleansing quality using the Harefield Cleansing Scale. Data on efficacy and tolerability are collected and analyzed. Participants are followed for about 30 hours after the last dose. The trial will end once 400 patients have completed participation.

A Trial to Compare Efficacy and Tolerability of Plenvu® and Picoprep® as Cleansing Agents Before Colonoscopy